Self-Amplifying mRNA Rabies Vaccine for Pets: Launch, FOIA Signals, and Open Questions

Merck’s new RNA-particle rabies vaccines for dogs and cats reached U.S. clinics in November 2026. They use self-amplifying technology that instructs cells to make the rabies protein. Earlier FOIA records on a related canine flu product list collapses and deaths within minutes of injection. Here is what the documents, company data, and independent reviews actually show so far.

Self-Amplifying mRNA Rabies Vaccine for Pets: Launch, FOIA Signals, and Open Questions

What Merck Launched and How It Works

On 2 November 2026 Merck Animal Health announced the U.S. availability of NOBIVAC NXT 1-Rabies and NOBIVAC NXT 3-Rabies. Both are licensed by the USDA for healthy dogs and cats 12 weeks of age or older. They are given as a 0.5 mL subcutaneous injection, contain no adjuvant, no preservatives, no antibiotics, and no thimerosal. The 3-year version claims duration of immunity of at least three years after the booster dose given one year after the first shot.

The platform is Merck’s RNA-particle technology. RNA particles derived from a modified Venezuelan equine encephalitis virus deliver self-amplifying RNA that codes for the rabies virus glycoprotein. Inside dendritic cells the RNA makes additional copies of itself for a limited period, so the cells produce the antigen that trains the immune system. The particles lack the genes needed to form new infectious particles, so they cannot spread as a virus. This is different from classic killed-virus rabies vaccines that contain inactivated whole virus plus, in many cases, an adjuvant.

Merck has already used the same platform in the United States for canine influenza H3N2 (Nobivac NXT Canine Flu) and for feline leukemia. The rabies versions expand the line. A peer-reviewed paper by researchers associated with the company reported that a single dose protected dogs and cats against virulent rabies challenge more than three years later.

The FOIA Records That Sparked Concern

Most of the public alarm centers on the earlier canine influenza product, not on the new rabies shots themselves. In April 2026 The HighWire published details from a FOIA request to the USDA covering roughly September 2024 through July 2025. The first 1,012 pages of nearly 1,900 pages of adverse-event reports listed Nobivac NXT Canine Flu H3N2 as a suspect product in 296 cases. Among them were four canine deaths (two with significant confounding factors), one feline death, three dogs euthanized, 41 neurological cases, 30 anaphylaxis or hypersensitivity reports, injection-site masses or fibrosis (some requiring surgery), and five collapse or shock-type presentations.

Two of the clearer cases involved rapid collapse: a 4-year-old golden retriever that went into cardiac arrest about 10 minutes after the shot, and a 7-year-old Yorkshire terrier that collapsed about 70 minutes later and could not be saved. Official field-safety summaries from controlled studies on the same product reported mostly mild events (lethargy the most common) at rates around 2.5 percent in one data set of roughly 650 dogs. Spontaneous post-market reports are not the same as controlled trials; they do not prove causation, but the volume and severity of some entries have led independent observers to call for more transparent, long-term monitoring.

Nicolas Hulscher and others have highlighted these FOIA pages and argued that the same platform is now being used for rabies without owners necessarily being told the technology involved. The People’s Voice article of 17 November 2026 repeated the FOIA findings and raised additional theoretical questions about how long amplification continues, individual variation, and possible shedding of antigen or RNA in bodily secretions.

What Official Sources and Fact-Checks Say

USDA product records list Nobivac NXT Rabies as a “Rabies Vaccine, RNA Particle.” Licensing studies included challenge protection and duration-of-immunity work. Steve Dale’s Pet World reviewed the public record in October 2026 and concluded that, at that time, no credible evidence showed dogs or cats dying because they received the rabies version. Claims of deaths were frequently conflated with the canine-flu product. Challenge studies euthanize control animals that develop rabies; that is not the same as vaccine-related death.

An AFP fact-check from December 2025 noted that the rabies product was not yet commercially available in the U.S. at that moment (it became available in November 2026) and that Canadian authorities and a virology professor stated there is no evidence the RNA vaccine can transmit rabies because it does not contain the full virus genome. Merck has pointed to its peer-reviewed safety and efficacy paper.

Rabies remains almost always fatal once clinical signs appear. Dog-mediated rabies still causes the large majority of the roughly 59,000 human deaths worldwide each year. In the United States the CDC has reported a rise in human exposures in 2026, with increased use of human rabies vaccine and immunoglobulin. Companion-animal vaccination is one of the main tools that keeps the virus from cycling between wildlife and people.

Open Questions That Remain

Self-amplifying RNA is designed to copy itself inside cells for a period of time. How long that continues in real-world dogs and cats of different ages, breeds, and health status is not fully detailed in public summaries. Individual variation and the cumulative effect of giving several RNA-particle products to the same animal are also untested in large, long-term independent studies.

Theoretical shedding of antigen or residual RNA in saliva or urine has been raised as a concern for human household members. No published evidence has shown infectious virus or clinically meaningful transfer, but the question has not been exhaustively studied in the home setting. Traditional killed-virus vaccines have decades of real-world use; the RNA-particle platform is newer.

Adverse-event reporting systems capture only a fraction of events and cannot by themselves prove cause. Controlled field-safety data so far show mostly mild reactions. Post-market signals on the related flu product include rare but serious outcomes that occurred close in time to injection. Both facts can be true at once. Continued independent surveillance and clear labeling so owners can ask which technology is in the syringe remain practical steps.

Related reading on this site includes earlier coverage of the USDA approval of self-amplifying products for pets and of early VAERS reports after a new human mRNA flu shot: USDA Quietly Approves Self-Amplifying mRNA Shots for Pets and Moderna mRNA Flu Shot: Early VAERS Reports.

What Owners Can Do Now

Ask the veterinarian the exact product name and whether it is an RNA-particle or traditional killed-virus vaccine. Request the package insert. Document the date, lot number, and any reaction. Report suspected adverse events through the veterinarian to the manufacturer and USDA. Rabies vaccination remains a legal requirement in most places and a proven public-health measure; the choice of which licensed product to use is still available in many clinics.

The record so far contains both encouraging efficacy data for the new platform and post-market signals on a related product that merit transparent follow-up. Readers can weigh the peer-reviewed challenge results, the FOIA pages, the official low rates of mild events, and the absence of proven transmission to humans, then decide what level of caution fits their household.

Original source: The People’s Voice, 17 November 2026. Additional primary documents include the Merck Animal Health announcement (2 November 2026), the HighWire FOIA summary (April 2026), the peer-reviewed Vaccines paper on three-year immunity, and USDA product listings.

Disclaimer for fact-checkers: This article reports claims and documents from multiple sources, including manufacturer materials, FOIA-derived adverse-event records, independent analyses, and fact-checks. Spontaneous reports do not establish causation. The source outlet The People’s Voice has published contested claims in the past; readers are encouraged to consult the primary USDA, Merck, and peer-reviewed records linked above and form their own judgment.


Original article: Self-Amplifying mRNA Rabies Vaccine for Pets: Launch, FOIA Signals, and Open Questions on Planet Today 🚀

Automatically republished from the main blog.

Post a Comment

What do you think? Share your opinion below – every comment matters! 😊
Please be respectful. Spamming or advertising is not allowed.

Previous Post Next Post

Contact Form